Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
PULM similar filings
- 25 Jan 23 Regulation FD Disclosure
- 11 Jan 23 Regulation FD Disclosure
- 4 Jan 23 Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine
- 14 Nov 22 Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
- 26 Sep 22 Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
- 10 Aug 22 Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
- 12 Jul 22 Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
Filing view
External links
Exhibit 99.2